BioReference Laboratories, Inc to Speak at the UBS Global Healthcare Conference

BioReference Laboratories, Inc to Speak at the UBS Global Healthcare
Conference

ELMWOOD PARK, N.J., May 15, 2013 (GLOBE NEWSWIRE) -- Bio-Reference
Laboratories, Inc (Nasdaq:BRLI) announced today that Marc D. Grodman M.D.,
President and Chief Executive Officer, is scheduled to speak at the 2013 UBS
Global Healthcare Conference on Monday, May 20^th, 2013, at The Sheraton Hotel
located in New York, NY. The BioReference Laboratories presentation is
scheduled to begin at 2:30 p.m. Eastern Daylight Time.

Those wishing to listen to the live audio webcast may access it on the
Company's corporate web site, www.bioreference.com or at the following site:
http://cc.talkpoint.com/ubsx001/052013b_ep/?entity=27_KMET4H1. Please go to
the site ten minutes before the presentation is ready to begin. You will need
to register as well as download and install any necessary audio software. The
webcast will be archived on the BioReference website for 30 days following the
call.

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases.BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995,
many of which are beyond our ability to control or predict. Forward-looking
statements may be identified by words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of
similar meaning and include, but are not limited to, statements about the
expected future business and financial performance of Bio-Reference
Laboratories, Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such statements involve
known and unknown risks and uncertainties that may cause the Company's actual
results in future periods to be materially different from any future
performance suggested herein. Risks and uncertainties that may affect the
future results of the company include, but are not limited to, adverse results
from future government investigations, lawsuits or private actions, including
the lawsuit described herein, the competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other and other risks and uncertainties
detailed from time to time in our filings with the Securities and Exchange
Commission.We undertake no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.

                             www.bioreference.com

CONTACT: Tara Mackay
         Investor Relations Coordinator
         (201) 791-2600
         (201) 791-1941 (fax)
         tmackay@bioreference.com